Sutro Biopharma, Inc.
STROSutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies and other biologics. It employs its proprietary Cell-Free Protein Synthesis platform to develop biologics with precise modification and enhanced efficiency. The company's pipeline includes bispecific antibodies, antibody-drug conjugates, and novel protein therapeutics aimed at treating various cancers and other diseases.
Company News
Sutro Biopharma initiated a Phase 1 clinical trial for STRO-004, a next-generation antibody-drug conjugate targeting tissue factor in various solid tumors. The trial aims to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity across multiple cancer types.
Sutro Biopharma announced the initiation of its Phase 1 study for STRO-004, a Tissue Factor ADC, and selected PTK7 as the target for its first dual-payload candidate STRO-227, showcasing its innovative antibody-drug conjugate platform.
Sutro Biopharma will present preclinical data on advanced antibody-drug conjugates (ADCs) at the 16th Annual World ADC Conference, highlighting innovations in dual-payload ADCs and cell-free manufacturing platforms to potentially improve cancer treatment.
The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.
The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.
